192 related articles for article (PubMed ID: 10381104)
21. Pharmacodynamics of moxifloxacin and levofloxacin against Streptococcus pneumoniae, Staphylococcus aureus, Klebsiella pneumoniae and Escherichia coli: simulation of human plasma concentrations after intravenous dosage in an in vitro kinetic model.
Odenholt I; Cars O
J Antimicrob Chemother; 2006 Nov; 58(5):960-5. PubMed ID: 16936293
[TBL] [Abstract][Full Text] [Related]
22. Pharmacodynamic comparisons of levofloxacin, ciprofloxacin, and ampicillin against Streptococcus pneumoniae in an in vitro model of infection.
Lacy MK; Lu W; Xu X; Tessier PR; Nicolau DP; Quintiliani R; Nightingale CH
Antimicrob Agents Chemother; 1999 Mar; 43(3):672-7. PubMed ID: 10049286
[TBL] [Abstract][Full Text] [Related]
23. Determining the frequency of resistance of Streptococcus pneumoniae to ciprofloxacin, levofloxacin, trovafloxacin, grepafloxacin, and gemifloxacin.
Evans ME
Eur J Clin Microbiol Infect Dis; 2001 Dec; 20(12):883-5. PubMed ID: 11837640
[TBL] [Abstract][Full Text] [Related]
24. Efficacy and pharmacodynamics of simulated human-like treatment with levofloxacin on experimental pneumonia induced with penicillin-resistant pneumococci with various susceptibilities to fluoroquinolones.
Croisier D; Chavanet P; Lequeu C; Ahanou A; Nierlich A; Neuwirth C; Piroth L; Duong M; Buisson M; Portier H
J Antimicrob Chemother; 2002 Sep; 50(3):349-60. PubMed ID: 12205059
[TBL] [Abstract][Full Text] [Related]
25. Pharmacodynamics of moxifloxacin and levofloxacin against Staphylococcus aureus and Staphylococcus epidermidis in an in vitro pharmacodynamic model.
Lister PD
Clin Infect Dis; 2001 Mar; 32 Suppl 1():S33-8. PubMed ID: 11249827
[TBL] [Abstract][Full Text] [Related]
26. Comparative efficacies of levofloxacin and ciprofloxacin against Streptococcus pneumoniae in a mouse model of experimental septicaemia.
Onyeji CO; Bui KQ; Owens RC; Nicolau DP; Quintiliani R; Nightingale CH
Int J Antimicrob Agents; 1999 Jul; 12(2):107-14. PubMed ID: 10418754
[TBL] [Abstract][Full Text] [Related]
27. The bactericidal activity of levofloxacin compared with ofloxacin, D-ofloxacin, ciprofloxacin, sparfloxacin and cefotaxime against Streptococcus pneumoniae.
George J; Morrissey I
J Antimicrob Chemother; 1997 Jun; 39(6):719-23. PubMed ID: 9222040
[TBL] [Abstract][Full Text] [Related]
28. Relative potential for selection of fluoroquinolone-resistant Streptococcus pneumoniae strains by levofloxacin: comparison with ciprofloxacin, sparfloxacin and ofloxacin.
Drugeon HB; Juvin ME; Bryskier A
J Antimicrob Chemother; 1999 Jun; 43 Suppl C():55-9. PubMed ID: 10404339
[TBL] [Abstract][Full Text] [Related]
29. In vitro infection model characterizing the effect of efflux pump inhibition on prevention of resistance to levofloxacin and ciprofloxacin in Streptococcus pneumoniae.
Louie A; Brown DL; Liu W; Kulawy RW; Deziel MR; Drusano GL
Antimicrob Agents Chemother; 2007 Nov; 51(11):3988-4000. PubMed ID: 17846144
[TBL] [Abstract][Full Text] [Related]
30. AUC(0-t)/MIC is a continuous index of fluoroquinolone exposure and predictive of antibacterial response for Streptococcus pneumoniae in an in vitro infection model.
Zelenitsky SA; Ariano RE; Iacovides H; Sun S; Harding GK
J Antimicrob Chemother; 2003 Apr; 51(4):905-11. PubMed ID: 12654762
[TBL] [Abstract][Full Text] [Related]
31. Induction of resistance of Streptococcus pneumoniae to quinolones in vitro.
Lafredo SC; Foleno BD; Fu KP
Chemotherapy; 1993; 39(1):36-9. PubMed ID: 8383031
[TBL] [Abstract][Full Text] [Related]
32. In vitro antimicrobial activity of levofloxacin against Streptococcus pneumoniae.
Hu BS; Fung CP; Liu PY; Lau YJ; Shi ZY; Lin YH
Zhonghua Yi Xue Za Zhi (Taipei); 1997 Oct; 60(4):191-4. PubMed ID: 9439047
[TBL] [Abstract][Full Text] [Related]
33. In-vitro activity of levofloxacin (l-ofloxacin), ofloxacin and ciprofloxacin against clinical isolates of Streptococcus pneumoniae obtained in England and Wales.
Johnson AP; Speller DC; Warner M; Domingue G
J Antimicrob Chemother; 1996 Nov; 38(5):907-8. PubMed ID: 8961064
[No Abstract] [Full Text] [Related]
34. Pharmacodynamics of levofloxacin and ofloxacin against Streptococcus pneumoniae.
Bauernfeind A
J Antimicrob Chemother; 1999 Jun; 43 Suppl C():77-82. PubMed ID: 10404343
[TBL] [Abstract][Full Text] [Related]
35. Activities of newer fluoroquinolones against ciprofloxacin-resistant Streptococcus pneumoniae.
Coyle EA; Kaatz GW; Rybak MJ
Antimicrob Agents Chemother; 2001 Jun; 45(6):1654-9. PubMed ID: 11353608
[TBL] [Abstract][Full Text] [Related]
36. Susceptibility of multi-resistant Streptococcus pneumoniae to ciprofloxacin, ofloxacin and levofloxacin.
Fuchs PC; Barry AL; Brown SD
J Antimicrob Chemother; 1997 May; 39(5):671-2. PubMed ID: 9184374
[No Abstract] [Full Text] [Related]
37. In-vitro activity of levofloxacin against Streptococcus pneumoniae with various levels of penicillin resistance.
Thomson KS; Chartrand SA; Sanders CC; Block SL
J Antimicrob Chemother; 1999 Jun; 43 Suppl C():15-9. PubMed ID: 10404332
[TBL] [Abstract][Full Text] [Related]
38. Anti-pneumococcal activity of gatifloxacin compared with other quinolone and non-quinolone agents.
Hoellman DB; Lin G; Jacobs MR; Appelbaum PC
J Antimicrob Chemother; 1999 May; 43(5):645-9. PubMed ID: 10382885
[TBL] [Abstract][Full Text] [Related]
39. Pharmacodynamics of levofloxacin and ciprofloxacin in a murine pneumonia model: peak concentration/MIC versus area under the curve/MIC ratios.
Scaglione F; Mouton JW; Mattina R; Fraschini F
Antimicrob Agents Chemother; 2003 Sep; 47(9):2749-55. PubMed ID: 12936969
[TBL] [Abstract][Full Text] [Related]
40. Serum bactericidal activity of levofloxacin against Streptococcus pneumoniae.
Shah PM
J Antimicrob Chemother; 1999 Jun; 43 Suppl C():61-5. PubMed ID: 10404340
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
